Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q4 FY24 results · Jan–Mar 2024
Alivus Life Sciences reported revenue from operations of ₹536.60 crore (down 13.6% from Q4 FY23) and net profit of ₹97.94 crore (down 33.1% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a standalone basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 536.60 | 621.32 | −13.6% | 572.80 | −6.3% |
| Other income | 3.13 | 2.84 | +10.4% | 1.69 | +85.2% |
| Total income | 539.73 | 624.16 | −13.5% | 574.50 | −6.1% |
| Profit before tax | 129.68 | 197.63 | −34.4% | 160.68 | −19.3% |
| Net profit for the period | 97.94 | 146.36 | −33.1% | 118.77 | −17.5% |
| EPS, basic (₹) | 7.99 | 11.94 | −33.1% | 9.69 | −17.5% |
| Net margin (%) | 18.3 | 23.6 | 20.7 |
Standalone
- Filed with BSE
- 26 Apr 2024, 14:48 IST
- Board meeting
- 25 Apr 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE